EXHIBIT
J

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-081

Gilead Colorado, Inc.
Attention: Ms. Linnea Tanner
Director, Regulatory Affairs
7575 West 103rd Ave., #102
Westmister, CO 80021-5426

Dear Ms. Tanner:

We have received your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Letairis (ambrisentan) 5 and 10 mg Tablets

Date of Application: December 13, 2006

Date of Receipt: December 18, 2006

Our Reference Number: NDA 22-081

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on February 16, 2007 in accordance with 21 CFR 314.101(a).

Please cite the NDA number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardiovascular and Renal Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you have any questions, please contact:

Ms. Melissa Robb
Regulatory Health Project Manager
(301) 796-1138

Sincerely,

{See appended electronic signature page}

Edward Fromm
Chief, Project Management Staff
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Edward Fromm
1/10/2007 02:31:37 PM